Navigation Links
Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Date:9/5/2007

ults, Stimuvax has entered its Phase III development and the START (Stimulating Targeted Antigenic Responses to NSCLC) trial is currently open for enrollment. The START trial is being conducted by Merck KGaA of Darmstadt, Germany, which has licensed worldwide development and commercialization rights to Stimuvax from Biomira. Stimuvax is being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.

"Patients with unresectable stage III non-small cell lung cancer have significant unmet medical need, and the START study is the first Phase III program to evaluate a therapeutic cancer vaccine in this population," said Dr. Robert L. Kirkman, MD, President and Chief Executive Officer of Biomira. "If these survival results are statistically confirmed in the Phase III trial, Stimuvax has the potential to become an important tool in the treatment of lung cancer."

According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in both men and women worldwide, with approximately 80% of cases classified as NSCLC. Current survival rates for NSCLC are low, with only 16% of patients alive five years post-diagnosis. Unfortunately for most patients, current treatments provide limited success. Stimuvax is an innovative cancer vaccine designed to stimulate the body's immune system to identify and destroy cancer cells expressing MUC1, a protein antigen that is widely expressed on common cancers including lung, breast and colorectal.

About the Phase II Trial

171 patients with ECOG 0-2 stage IIIB/IV NSCLC with stable or responding disease after any first-line chemotherapy with or without radiotherapy were randomized to receive Stimuvax plus BSC or BSC alone. Patients were stratified by stage of disease (IIIB LR or stage IIIB with malignant pleural effusion, and stage IV). Patients in the Stimuvax arm received a single intravenous dose of cyclophosphamide 300mg/m2 followed by 8 weekly subcutane
'/>"/>

SOURCE Biomira Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
(Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
(Date:8/19/2014)... To improve students, chances of completing introductory ... of Houston (UH) implemented a comprehensive student success ... for failure. , Through a grant from ... Department of Biology and Biochemistry embarked on a ... Biology" for non-majors and "Introductory Biology" for science ...
(Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
(Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... The decline of large predators and other "apex consumers" at ... the planet. The finding is reported by an international ... of the journal Science . The study looked ... and marine ecosystems and concluded "the loss of apex consumers ...
... 14, 2011 Two studies published in the current ... that consuming in-shell pistachios is a weight-wise approach to ... curb consumption and decrease calorie intake. ... pistachios ate 41-percent fewer calories compared to those who ...
... East Coast may be at risk to higher sea levels ... years, according to a new study by NOAA. The ... surges along the East Coast during the 2009-2010 El Nio ... NOAA,s Center for Operational Oceanographic Products and Services, examined water ...
Cached Biology News:Loss of large predators caused widespread disruption of ecosystems 2Loss of large predators caused widespread disruption of ecosystems 3In-shell pistachios: The original 'slow food?' 2In-shell pistachios: The original 'slow food?' 3Strong El Niño could bring increased sea levels, storm surges to US East Coast 2
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Newborn Bovine Serum Heat-Inactivated...
Performance, mycoplasma, virus, and endotoxin tested...
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Biology Products: